NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus...
NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus...
NewAmsterdam Pharma Presents Additional Data From Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib In Patients With Heterozygous Familial Hypercholesterolemia At AHA Scientific Sessions 2024; Met Primary Endpoint With LDL-C Mean Reduction Versus Placebo Of 36.3% At Day 84 And 41.5% At Day 365
NewAmsterdam Pharma在2024年美国心脏协会科学会议上发布了关于评估Obicetrapib在患有杂合子家族性高胆固醇血症患者中的第三阶段BROOKLYN临床试验的额外数据；在第84天与安慰剂相比，LDL-C的平均降低达到36.3%，在第365天达到了41.5%。
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –
– 在第84天与安慰剂相比，LDL-C的平均降低达到36.3%，在第365天达到41.5% –
– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –
– Lp(a)在第84天与安慰剂相比减少了45.9%，在第365天减少了54.3% –
– Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% –
– 总LDL-P在第180天与安慰剂相比减少了52.5%，小LDL-P减少了102.4% –
– Safety results comparable to placebo –
– 安全性结果与安慰剂相当 –
NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia ("HeFH"), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The data were presented today in an oral late-breaker presentation at the American Heart Association (AHA) Scientific Sessions.
荷兰纳尔登和美国迈阿密，2024年11月18日（GLOBE NEWSWIRE）——NewAmsterdam Pharma Company N.V.（纳斯达克：NAMS）是一家晚期临床生物制药公司，致力于开发针对具有心血管疾病（"CVD"）风险且低密度脂蛋白胆固醇（"LDL-C"）升高患者的口服非他汀类药物，现有治疗方案不能够有效或耐受，今天宣布了该公司第三阶段BROOKLYN临床试验（NCT05425745）评估在尽管接受了最大耐受的降脂治疗但LDL-C未得到有效控制的杂合子家族性高胆固醇血症（"HeFH"）成人患者中使用obicetrapib的额外结果。今天在美国心脏协会（AHA）科学会议上进行了口头晚期报告。
